GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt
· Delayed Price · Currency is EGP 41.18
+0.76 (1.88%)
At close: Jun 4, 2025
GlaxoSmithKline S.A.E Cash Flow Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 242.09 | 173.98 | 60.46 | 735.38 | 154.64 | 28.13 | Upgrade
|
| Depreciation & Amortization | 54.11 | 52.92 | 47.79 | 49.81 | 57.19 | 28.4 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.79 | 2.4 | -0.17 | -5.94 | -0.24 | -0.15 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 137.65 | 101 | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | -24.17 | -1 | 18.12 | -12.15 | 9.21 | 19.49 | Upgrade
|
| Provision & Write-off of Bad Debts | 42.32 | 64.64 | -18.66 | 11.01 | 30.79 | 56.87 | Upgrade
|
| Other Operating Activities | 398.79 | 386.52 | 24.11 | -530.26 | 89.78 | 222.88 | Upgrade
|
| Change in Accounts Receivable | -309.35 | -333.87 | -366.5 | -231.15 | -18.53 | -147.25 | Upgrade
|
| Change in Inventory | -921.28 | -420.25 | -263.59 | -47.2 | -42.95 | -84.47 | Upgrade
|
| Change in Accounts Payable | -4.11 | 64.9 | 156.24 | -322.32 | 45.45 | -28.54 | Upgrade
|
| Change in Other Net Operating Assets | 411.18 | -394.38 | 506.84 | -82.97 | -133.15 | -96.51 | Upgrade
|
| Operating Cash Flow | -108.62 | -404.15 | 302.27 | 1,036 | 192.19 | -1.17 | Upgrade
|
| Operating Cash Flow Growth | - | - | -70.82% | 439.06% | - | - | Upgrade
|
| Capital Expenditures | -98.01 | -124.34 | -77.08 | -48.76 | -35.76 | -53.67 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 5.42 | 6.99 | 0.61 | 0.17 | Upgrade
|
| Other Investing Activities | 33.39 | -101.72 | 157.15 | -200 | - | - | Upgrade
|
| Investing Cash Flow | -64.62 | -226.07 | 85.5 | -241.77 | -35.15 | -53.5 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -118.21 | -27.52 | -89.43 | Upgrade
|
| Long-Term Debt Repaid | - | -43.38 | -28.98 | -19.21 | -24.11 | - | Upgrade
|
| Total Debt Repaid | -86.44 | -43.38 | -28.98 | -137.43 | -51.63 | -89.43 | Upgrade
|
| Net Debt Issued (Repaid) | -86.44 | -43.38 | -28.98 | -137.43 | -51.63 | -89.43 | Upgrade
|
| Common Dividends Paid | -69.67 | -69.67 | -131.59 | -111.04 | -5.58 | -5.58 | Upgrade
|
| Other Financing Activities | -11.93 | -10.6 | 16.3 | -33.5 | -48.42 | -79.37 | Upgrade
|
| Financing Cash Flow | -168.04 | -123.66 | -144.28 | -281.97 | -105.63 | -174.38 | Upgrade
|
| Net Cash Flow | -341.28 | -753.87 | 243.49 | 512.29 | 51.41 | -229.05 | Upgrade
|
| Free Cash Flow | -206.63 | -528.49 | 225.2 | 987.26 | 156.43 | -54.84 | Upgrade
|
| Free Cash Flow Growth | - | - | -77.19% | 531.14% | - | - | Upgrade
|
| Free Cash Flow Margin | -6.32% | -17.67% | 10.05% | 54.15% | 8.63% | -2.75% | Upgrade
|
| Free Cash Flow Per Share | -2.47 | -6.33 | 2.70 | 11.82 | 1.87 | -0.66 | Upgrade
|
| Cash Interest Paid | 11.93 | 10.6 | 37.96 | 33.5 | 48.67 | 79.91 | Upgrade
|
| Cash Income Tax Paid | 48.27 | 48.27 | 173.04 | 10.72 | 29.97 | 8.74 | Upgrade
|
| Levered Free Cash Flow | -336.72 | -523.15 | 178.77 | 108.37 | 49.65 | 95.72 | Upgrade
|
| Unlevered Free Cash Flow | -329.27 | -516.53 | 202.5 | 129.31 | 80.07 | 145.66 | Upgrade
|
| Change in Net Working Capital | 565.04 | 711.27 | 48.73 | -118.68 | 92.7 | -44.36 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.